How is your patient’s tumor profiled?
Tumor tissue is obtained during biopsy or surgery and the oncologist will send that tissue to our CLIA certified laboratory using our special collection kit. Two samples of the tumor tissue are obtained, fixed and live. The fixed tumor tissue is used for a panel of biomarker tests (e.g. BRAF, HER2 etc) using genomics. The live tumor tissue is grown in the lab and used to test the drug response of the tumor to a panel standard-of-care (SOC) drugs. When testing is complete a report is provided back to the clinician with recommended SOC therapies based on the drug response and genomic profiles.
Why individualize your patient’s therapy?
Clinical validation of in vitro cell-based profiling
14 mo improvement in overall survival
50% percentage improvement in progressive free survival
2.5x longer life-span for patients treated with ChemoFX specified agent
51% potential for savings for ovarian cancer treatment
Informative, clear Final Report
The Precision Oncology Insights process
Data from the patient
Data from the patient’s tumor (functional tumor testing)
Compare to TumorSpace knowledgebase of genomic and drug response profiles
Information “roadmap” to empower the oncologist to individualize therapy
Oncologist determines course of treatment for the patient